Switch theme
Sign up to access all valuation multiples
Bioretec Ltd is a medical device company focusing on the development of safe, and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. The company's products are used world wide and continue to further develop materials and products for high-load-bearing clinical applications. Some of its brands include RemeOs, Activa IM-N, ActivaPi, and ActivaScrew.
2003
37
LTM Revenue $5.6M
LTM EBITDA -$4.9M
$54.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bioretec has a last 12-month revenue of $5.6M and a last 12-month EBITDA of -$4.9M.
In the most recent fiscal year, Bioretec achieved revenue of $4.9M and an EBITDA of -$4.4M.
Bioretec expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bioretec valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $4.2M | $4.9M | XXX | XXX | XXX |
| Gross Profit | $2.3M | $2.9M | XXX | XXX | XXX |
| Gross Margin | 55% | 60% | XXX | XXX | XXX |
| EBITDA | -$2.9M | -$4.4M | XXX | XXX | XXX |
| EBITDA Margin | -70% | -89% | XXX | XXX | XXX |
| Net Profit | -$2.6M | -$4.1M | XXX | XXX | XXX |
| Net Margin | -62% | -83% | XXX | XXX | XXX |
| Net Debt | $0.5M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bioretec's stock price is EUR 2 (or $2).
Bioretec has current market cap of EUR 55.0M (or $59.1M), and EV of EUR 50.5M (or $54.2M).
See Bioretec trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $54.2M | $59.1M | XXX | XXX | XXX | XXX | $-0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bioretec has market cap of $59.1M and EV of $54.2M.
Bioretec's trades at 9.6x LTM EV/Revenue multiple, and -11.2x LTM EBITDA.
Analysts estimate Bioretec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bioretec and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $54.2M | XXX | XXX | XXX |
| EV/Revenue | 11.1x | XXX | XXX | XXX |
| EV/EBITDA | -12.5x | XXX | XXX | XXX |
| P/E | -11.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBioretec's NTM/LTM revenue growth is 63%
Bioretec's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Bioretec's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bioretec's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bioretec and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -89% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 48% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -26% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 163% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bioretec acquired XXX companies to date.
Last acquisition by Bioretec was XXXXXXXX, XXXXX XXXXX XXXXXX . Bioretec acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bioretec founded? | Bioretec was founded in 2003. |
| Where is Bioretec headquartered? | Bioretec is headquartered in Finland. |
| How many employees does Bioretec have? | As of today, Bioretec has 37 employees. |
| Is Bioretec publicy listed? | Yes, Bioretec is a public company listed on HEL. |
| What is the stock symbol of Bioretec? | Bioretec trades under BRETEC ticker. |
| When did Bioretec go public? | Bioretec went public in 2022. |
| Who are competitors of Bioretec? | Similar companies to Bioretec include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Bioretec? | Bioretec's current market cap is $59.1M |
| What is the current revenue of Bioretec? | Bioretec's last 12-month revenue is $5.6M. |
| What is the current EBITDA of Bioretec? | Bioretec's last 12-month EBITDA is -$4.9M. |
| What is the current EV/Revenue multiple of Bioretec? | Current revenue multiple of Bioretec is 9.6x. |
| What is the current EV/EBITDA multiple of Bioretec? | Current EBITDA multiple of Bioretec is -11.2x. |
| What is the current revenue growth of Bioretec? | Bioretec revenue growth between 2023 and 2024 was 16%. |
| Is Bioretec profitable? | Yes, Bioretec is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
